Puma Biotechnology Stock Price, News & Analysis (NASDAQ:PBYI)

$100.75 -4.25 (-4.05 %)
(As of 12/11/2017 08:13 AM ET)
Previous Close$105.00
Today's Range$99.70 - $108.20
52-Week Range$28.35 - $136.90
Volume1.24 million shs
Average Volume1.09 million shs
Market Capitalization$3.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.73

About Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology logoPuma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Receive PBYI News and Ratings via Email

Sign-up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500

Debt

Debt-to-Equity RatioN/A
Current Ratio1.23%
Quick Ratio1.23%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.70 per share
Price / Book17.68

Profitability

Trailing EPS($8.18)
Net Income$-276,010,000.00
Net MarginsN/A
Return on Equity-208.58%
Return on Assets-145.91%

Miscellaneous

Employees160
Outstanding Shares37,530,000

Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions

What is Puma Biotechnology's stock symbol?

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology Inc (NASDAQ:PBYI) released its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($2.50) by $0.43. The biopharmaceutical company earned $6.10 million during the quarter, compared to analysts' expectations of $3.78 million. During the same quarter last year, the business earned ($1.11) earnings per share. View Puma Biotechnology's Earnings History.

When will Puma Biotechnology make its next earnings announcement?

Puma Biotechnology is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Puma Biotechnology.

Where is Puma Biotechnology's stock going? Where will Puma Biotechnology's stock price be in 2017?

9 brokerages have issued 12-month target prices for Puma Biotechnology's stock. Their forecasts range from $92.00 to $164.00. On average, they anticipate Puma Biotechnology's share price to reach $130.67 in the next year. View Analyst Ratings for Puma Biotechnology.

Who are some of Puma Biotechnology's key competitors?

Who are Puma Biotechnology's key executives?

Puma Biotechnology's management team includes the folowing people:

  • Alan H. Auerbach, Chairman of the Board, President, Chief Executive Officer (Age 47)
  • Charles R. Eyler, Senior Vice President - Finance and Administration, Treasurer (Age 69)
  • Richard P. Bryce, Chief Scientific Officer, Chief Medical Officer (Age 59)
  • Steven Lo, Chief Commercial Officer (Age 50)
  • Jay M. Moyes, Independent Director (Age 63)
  • Adrian M Senderowicz, Independent Director (Age 53)
  • Troy E. Wilson Ph.D. J.D., Independent Director (Age 48)
  • Frank E. Zavrl, Independent Director (Age 51)

Who owns Puma Biotechnology stock?

Puma Biotechnology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (5.04%), Perceptive Advisors LLC (2.46%), Point72 Asset Management L.P. (1.28%), Emerald Advisers Inc. PA (0.99%), Schroder Investment Management Group (0.93%) and Emerald Mutual Fund Advisers Trust (0.78%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.

Who sold Puma Biotechnology stock? Who is selling Puma Biotechnology stock?

Puma Biotechnology's stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Canada Pension Plan Investment Board, C WorldWide Group Holding A S, Neuberger Berman Group LLC, California State Teachers Retirement System, Cornerstone Capital Management Holdings LLC., Stifel Financial Corp and Principal Financial Group Inc.. Company insiders that have sold Puma Biotechnology company stock in the last year include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Insider Buying and Selling for Puma Biotechnology.

Who bought Puma Biotechnology stock? Who is buying Puma Biotechnology stock?

Puma Biotechnology's stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Perceptive Advisors LLC, Nicholas Investment Partners LP, Emerald Advisers Inc. PA, Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, Dimensional Fund Advisors LP and Sanctuary Wealth Advisors LLC. View Insider Buying and Selling for Puma Biotechnology.

How do I buy Puma Biotechnology stock?

Shares of Puma Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Puma Biotechnology's stock price today?

One share of Puma Biotechnology stock can currently be purchased for approximately $100.75.

How big of a company is Puma Biotechnology?

Puma Biotechnology has a market capitalization of $3.78 billion. The biopharmaceutical company earns $-276,010,000.00 in net income (profit) each year or ($8.18) on an earnings per share basis. Puma Biotechnology employs 160 workers across the globe.

How can I contact Puma Biotechnology?

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]


MarketBeat Community Rating for Puma Biotechnology (PBYI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  527
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Puma Biotechnology (NASDAQ:PBYI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.892.892.88
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $130.67$130.67$113.11$93.43
Price Target Upside: 26.86% upside26.86% upside8.50% upside11.69% upside

Puma Biotechnology (NASDAQ:PBYI) Consensus Price Target History

Price Target History for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ:PBYI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Credit Suisse GroupBoost Price TargetOutperform$136.00 -> $142.00N/AView Rating Details
11/10/2017BarclaysReiterated RatingBuy$103.00 -> $122.00N/AView Rating Details
11/10/2017CitigroupBoost Price TargetBuy -> Buy$156.00 -> $164.00N/AView Rating Details
11/10/2017Royal Bank Of CanadaLower Price TargetSector Perform$108.00 -> $92.00N/AView Rating Details
10/27/2017Leerink SwannBoost Price TargetPositive -> Outperform$140.00N/AView Rating Details
10/9/2017Bank of AmericaReiterated RatingBuy$117.00 -> $135.00N/AView Rating Details
10/4/2017J P Morgan Chase & CoReiterated RatingBuy$131.00HighView Rating Details
10/2/2017Stifel NicolausBoost Price TargetBuy$110.00 -> $130.00LowView Rating Details
7/22/2017CowenReiterated RatingOutperform$91.00 -> $120.00MediumView Rating Details
1/5/2016Berenberg BankUpgradeHold -> BuyN/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Puma Biotechnology (NASDAQ:PBYI) Earnings History and Estimates Chart

Earnings by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ PBYI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($1.97)N/AView Earnings Details
11/9/2017Q3 2017($2.50)($2.07)$3.78 million$6.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.32)($2.10)ViewN/AView Earnings Details
5/10/2017Q1 2017($2.06)($1.97)ViewN/AView Earnings Details
3/1/2017Q4($1.92)($2.04)ViewN/AView Earnings Details
5/10/2016Q1($1.99)($1.28)ViewN/AView Earnings Details
2/29/2016Q4($1.95)($1.23)ViewN/AView Earnings Details
11/9/2015Q3($1.84)($1.87)ViewN/AView Earnings Details
8/10/2015Q2($1.55)($1.13)ViewN/AView Earnings Details
5/11/2015Q1($1.25)($1.02)ViewN/AView Earnings Details
3/2/2015($1.15)($1.59)ViewN/AView Earnings Details
11/10/2014($1.27)($1.19)ViewN/AView Earnings Details
8/11/2014Q214($0.66)($1.05)ViewN/AView Earnings Details
5/12/2014($0.48)($0.67)ViewN/AView Earnings Details
3/3/2014Q413($0.49)($0.46)ViewN/AView Earnings Details
4/1/2013Q413($0.70)($0.25)ViewN/AView Earnings Details
11/14/2012Q312($1.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Puma Biotechnology (NASDAQ:PBYI) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($2.03)($2.03)($2.03)
Q3 20171($2.20)($2.20)($2.20)
Q4 20171($1.96)($1.96)($1.96)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Puma Biotechnology (NASDAQ:PBYI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Puma Biotechnology (NASDAQ PBYI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.10%
Institutional Ownership Percentage: 96.05%
Insider Trades by Quarter for Puma Biotechnology (NASDAQ:PBYI)
Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Puma Biotechnology (NASDAQ PBYI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Charles R EylerInsiderSell1,322$105.46$139,418.12View SEC Filing  
9/29/2017Richard Paul BryceSVPSell15,000$120.00$1,800,000.00View SEC Filing  
9/7/2017Richard Paul BryceSVPSell15,000$100.09$1,501,350.00View SEC Filing  
7/20/2017Alan H AuerbachInsiderSell13,175$94.73$1,248,067.75View SEC Filing  
7/20/2017Richard Paul BryceSVPSell1,998$94.48$188,771.04View SEC Filing  
7/3/2017Richard Paul BryceSVPSell5,000$87.10$435,500.00View SEC Filing  
6/12/2017Adage Capital Partners Gp, L.LMajor ShareholderSell247,260$80.32$19,859,923.20View SEC Filing  
6/5/2017Adage Capital Partners Gp, L.LMajor ShareholderSell507,128$87.84$44,546,123.52View SEC Filing  
5/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,235,700$75.38$93,147,066.00View SEC Filing  
2/1/2017Robert CharnasInsiderSell3,008$31.83$95,744.64View SEC Filing  
1/20/2017Alan H AuerbachInsiderSell10,202$33.24$339,114.48View SEC Filing  
1/20/2017Richard Paul BryceSVPSell2,293$33.24$76,219.32View SEC Filing  
7/6/2015Richard Paul BryceSVPSell3,000$110.03$330,090.00View SEC Filing  
11/8/2013Adage Capital Partners Gp Llcmajor shareholderBuy22,549$38.92$877,607.08View SEC Filing  
11/5/2013Adage Capital Partners Gp Llcmajor shareholderBuy280,700$39.60$11,115,720.00View SEC Filing  
10/9/2013Adage Capital Partners Gp Llcmajor shareholderBuy140,900$40.44$5,697,996.00View SEC Filing  
12/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy29,560$19.00$561,640.00View SEC Filing  
12/12/2012Adage Capital Partners Gp LlcMajor ShareholderBuy30,400$19.00$577,600.00View SEC Filing  
12/11/2012Adage Capital Partners Gp LlcMajor ShareholderBuy140,040$18.98$2,657,959.20View SEC Filing  
10/24/2012Thomas MalleyDirectorBuy10,000$16.00$160,000.00View SEC Filing  
10/18/2012Adage Capital Partners Gp LlcMajor ShareholderBuy610,000$16.00$9,760,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Puma Biotechnology (NASDAQ PBYI) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Post -$2.04 Earnings Per ShareZacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) to Post -$2.04 Earnings Per Share
www.americanbankingnews.com - December 11 at 1:26 AM
Puma (PBYI) Stock Up More than 200% This Year: Heres WhyPuma (PBYI) Stock Up More than 200% This Year: Here's Why
www.zacks.com - December 8 at 4:32 PM
An Intrinsic Value Calculation For Puma Biotechnology Inc (PBYI) Shows It’s 48.79% UndervaluedAn Intrinsic Value Calculation For Puma Biotechnology Inc (PBYI) Shows It’s 48.79% Undervalued
finance.yahoo.com - December 8 at 10:19 AM
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San ...Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San ...
www.businesswire.com - December 7 at 4:52 PM
EXACT Sciences (EXAS) vs. Puma Biotechnology (PBYI) Head-To-Head SurveyEXACT Sciences (EXAS) vs. Puma Biotechnology (PBYI) Head-To-Head Survey
www.americanbankingnews.com - December 7 at 1:16 PM
Puma Biotech (PBYI) Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment ... - StreetInsider.comPuma Biotech (PBYI) Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment ... - StreetInsider.com
www.streetinsider.com - December 6 at 4:37 PM
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer SymposiumPuma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
finance.yahoo.com - December 6 at 4:37 PM
Charles R. Eyler Sells 1,322 Shares of Puma Biotechnology Inc (PBYI) StockCharles R. Eyler Sells 1,322 Shares of Puma Biotechnology Inc (PBYI) Stock
www.americanbankingnews.com - December 5 at 9:30 PM
Analyzing Puma Biotechnology (PBYI) and Qiagen (QGEN)Analyzing Puma Biotechnology (PBYI) and Qiagen (QGEN)
www.americanbankingnews.com - December 2 at 3:28 AM
Puma Biotechnology Inc (PBYI) Downgraded by BidaskClub to BuyPuma Biotechnology Inc (PBYI) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - November 26 at 6:10 AM
Zacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $18.05 MillionZacks: Analysts Anticipate Puma Biotechnology Inc (PBYI) Will Post Quarterly Sales of $18.05 Million
www.americanbankingnews.com - November 25 at 10:40 AM
Puma Biotechnology Inc (PBYI) Receives Average Rating of "Buy" from AnalystsPuma Biotechnology Inc (PBYI) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 23 at 3:34 PM
Puma Biotech (PBYI) Says Breast Cancer Drug to be Made Available in Australia, New Zealand and South East AsiaPuma Biotech (PBYI) Says Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia
www.streetinsider.com - November 23 at 7:21 AM
New Early- Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia Following License DealNew Early- Breast Cancer Drug to be Made Available in Australia, New Zealand and South East Asia Following License Deal
finance.yahoo.com - November 23 at 7:21 AM
Puma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.04 Per SharePuma Biotechnology Inc (PBYI) Expected to Post Earnings of -$2.04 Per Share
www.americanbankingnews.com - November 23 at 1:26 AM
Puma Biotechnology (PBYI) Presents At Stifel 2017 Healthcare Conference - SlideshowPuma Biotechnology (PBYI) Presents At Stifel 2017 Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 10:46 AM
Puma Biotechnology Target of Unusually High Options Trading (PBYI)Puma Biotechnology Target of Unusually High Options Trading (PBYI)
www.americanbankingnews.com - November 16 at 2:06 AM
5 Major Clinical Trial Results Coming Up5 Major Clinical Trial Results Coming Up
247wallst.com - May 25 at 9:40 AM
Puma Biotech (PBYI) Secures Slot to Present at ASCO 2016; Offers Details - StreetInsider.comPuma Biotech (PBYI) Secures Slot to Present at ASCO 2016; Offers Details - StreetInsider.com
www.streetinsider.com - May 18 at 10:27 PM
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andPUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - May 10 at 5:16 PM
PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly ReportPUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - May 10 at 4:44 PM
Puma Biotechs (PBYI) Neratinib Poster Presentations Featured at AACR 2016 - StreetInsider.comPuma Biotech's (PBYI) Neratinib Poster Presentations Featured at AACR 2016 - StreetInsider.com
www.streetinsider.com - April 21 at 6:19 AM
PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsPUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 30 at 6:17 AM
The 52-Week Low Club for TuesdayThe 52-Week Low Club for Tuesday
247wallst.com - March 29 at 4:04 PM
Why Puma Biotechnologys Shares Are Crashing TodayWhy Puma Biotechnology's Shares Are Crashing Today
www.fool.com - March 29 at 12:44 PM

SEC Filings

Puma Biotechnology (NASDAQ:PBYI) SEC Filings

DateFilerForm TypeView
12/06/2017
3:03 PM
Puma Biotechnology (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
View Filing
12/05/2017
3:06 PM
EYLER CHARLES R (Reporting)
Puma Biotechnology (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Puma Biotechnology (NASDAQ:PBYI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Puma Biotechnology (NASDAQ PBYI) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.